3-(3-hydroxy-2,4,6-trichlorophenyl)-propanoic acid | 274928-12-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(3-hydroxy-2,4,6-trichlorophenyl)-propanoic acid
• 英文别名: 3-(3-Hydroxy-2,4,6-trichlorophenyl)propanoic acid；3-(2,4,6-trichloro-3-hydroxyphenyl)propanoic acid
• CAS: 274928-12-0
• 化学式: C₉H₇Cl₃O₃
• 分子量: 269.512
• InChiKey: GKKSYDVFIYCWFP-UHFFFAOYSA-N

物化性质

• 沸点：
  390.2±37.0 °C(Predicted)
• 密度：
  1.607±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-hydroxy-2,4,6-trichlorophenyl)-propanoic acid 在 potassium carbonate 、 sodium iodide 、 potassium hydroxide 作用下， 反应 10.0h， 生成
  参考文献：
  名称：

  咪鲜胺半抗原、人工抗原和抗体及其制备方法和应用

  摘要：

  本发明公开了咪鲜胺半抗原、人工抗原和抗体及其制备方法和应用，本发明提供的咪鲜胺半抗原既最大程度保留了咪鲜胺的特征结构，使得咪鲜胺半抗原的免疫原性明显增强，又具有可以与载体蛋白发生偶联的羧基；用咪鲜胺半抗原与载体蛋白偶联后得到的咪鲜胺免疫抗原去免疫动物，更有利于刺激动物免疫应答产生特异性更强、灵敏度更高的抗体，经检测咪鲜胺抗体的灵敏度可达0.1μg/L，与其他农药的交叉反应率低，为后续建立咪鲜胺的各种免疫分析方法提供了基础。

  公开号：

  CN110627726B
• 作为产物：
  描述：

  间-香豆酸 在 lead 、 sodium hydroxide 、 磺酰氯 、 硫酸 、 sodium 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 28.0h， 生成 3-(3-hydroxy-2,4,6-trichlorophenyl)-propanoic acid
  参考文献：
  名称：

  Development of an Immunochemical Technique for the Analysis of Trichlorophenols Using Theoretical Models

  摘要：

  已开发出一种免疫测定法用于三氯苯酚分析，该方法基于理论化学建模研究。这些数据使我们能够根据与目标分析物的实际相似性选择最佳的免疫刺激物化学结构。该化合物的合成及随后的适当免疫协议的应用，导致产生了针对目标分析物的多克隆抗体。开发了一种同源直接竞争ELISA，整个过程大约只需1小时。其最小检测限为0.2 ± 0.06 μg/L（1.01 ± 0.3 nM），并已证明能够耐受较宽范围的离子强度和pH值。因此，该测定法在离子强度在4到56 mS/cm及pH值在5.5到9.5的样本中具有可接受的特性。对该免疫测定法选择性的研究表明，对相应溴化类似物具有高识别性。其他酚类化合物在使用该免疫化学技术分析2,4,6-三氯苯酚时不会显著干扰。测定法的准确性已通过认证样品和加标样品进行评估。

  DOI：

  10.1021/ac991336y

文献信息

• Competitive Quenching Fluorescence Immunoassay for Chlorophenols Based on Laser-Induced Fluorescence Detection in Microdroplets
  作者：Mikaela Nichkova、Jun Feng、Francisco Sanchez-Baeza、M.-Pilar Marco、Bruce D. Hammock、Ian M. Kennedy

  DOI：10.1021/ac025933n

  日期：2003.1.1

  An improved biomonitoring system for the analysis of 2,4,6-trichlorophenol (TCP) in urine samples has been developed. The principle of the biosensor device is the detection of laser-induced fluorescence (LIF) in single microdroplets by a homogeneous quenching fluorescence immunoassay (QFIA). The competitive immunoassay occurs in microdroplets (d = 58,4 μm) produced by a piezoelectric generator system with 10-μm-diameter orifice. A continuous Ar ion laser (488 nm) excites the fluorescent tracer; its fluorescence is detected by a spectrometer attached to a 512 × 512 cooled, charge-coupled device camera. Fluorescence is quenched by specific binding of TCP polyclonal antibodies to the fluorescent tracer (hapten A−fluorescein); the quenching effect is diminished by the presence of the analyte. Thus, an increase in the signal is produced in a positive dose-dependent manner when TCP is present in the sample. In 10 mM PBS buffer, the IC50 of the LIF-microdroplet QFIA is 0.45 μg L-1 reaching a LOD of 0.04 μg L-1. The QFIA with the same reagents performed in microtiter plate format achieved a LOD of 0.36 μg L-1 in buffer solution. Performance in human urine was similar to that observed in the buffer. A LOD of 1.6 μg L-1, with a dynamic range between 4 and 149.5 μg L-1 in urine, was obtained without any sample treatment other than dilution with the assay buffer. The detectability achieved is sufficient for occupational exposure risk assessment.

  一种改进的生物监测系统已被开发，用于分析尿液样本中的2,4,6-三氯苯酚（TCP）。该生物传感器设备的原理是通过均相淬灭荧光免疫分析（QFIA）检测单个微液滴中的激光诱导荧光（LIF）。竞争性免疫分析在由压电发生器系统产生的直径为58.4微米的微液滴中进行，液滴孔径为10微米。连续的氩离子激光（488纳米）激发荧光示踪剂；其荧光通过连接到512 × 512冷却电荷耦合器件相机的光谱仪进行检测。荧光通过TCP多克隆抗体与荧光示踪剂（半抗原A-荧光素）的特异性结合而被淬灭；分析物的存在减少了淬灭效应。因此，当样本中存在TCP时，信号以正剂量依赖的方式增加。在10 mM PBS缓冲液中，LIF-微液滴QFIA的IC50为0.45 μg L-1，达到的检测限（LOD）为0.04 μg L-1。使用相同试剂在微孔板格式下进行的QFIA在缓冲溶液中实现了0.36 μg L-1的检测限。人尿中的性能与在缓冲液中观察到的相似。获得的尿液检测限为1.6 μg L-1，动态范围在4到149.5 μg L-1之间，只有通过试剂缓冲液进行稀释而无需其他样本处理。所达到的可检测性足以用于职业接触风险评估。
• PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20200087399A1

  公开（公告）日：2020-03-19

  Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
• [EN] PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS<br/>[FR] AGENTS DE CIBLAGE DE TUMEUR À LYMPHOCYTES T CAR (CTCT) D'ÉTHER DE PHOSPHOLIPIDE (PLE)
  申请人：SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST

  公开号：WO2018148224A1

  公开（公告）日：2018-08-16

  Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
• [EN] ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN<br/>[FR] PROTÉINES DE FUSION INDUCTIBLES PAR ACTIVITÉ AYANT UN DOMAINE DE LIAISON À LA PROTÉINE DE CHOC THERMIQUE 90
  申请人：[en]SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE

  公开号：WO2022174035A2

  公开（公告）日：2022-08-18

  Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.